Eledon Pharmaceuticals, Inc. (ELDN)

USD 4.18

(-7.11%)

Market Cap (In USD)

249.71 Million

Revenue (In USD)

-

Net Income (In USD)

-40.32 Million

Avg. Volume

77.05 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.43-5.54
PE
-
EPS
-
Beta Value
0.766
ISIN
US28617K1016
CUSIP
28617K101
CIK
1404281
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. David-Alexandre C. Gros M.D., Ph.D.
Employee Count
-
Website
https://eledon.com
Ipo Date
2014-09-17
Details
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.